Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
487 questions in 49 reviews · Breast Cancer
current versionsNo studies 44 · 9%Ungraded 14 · 2.9%Very low 108 · 22.2%Low 128 · 26.3%Moderate 107 · 22%High 86 · 17.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Shoulder range of motion for forward flexion ‐ short term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment Conservative interventions for preventing clinically detectable upper‐limb lymphoedema in patients who are… (2015) · Cochrane | no estimate extracted | 3 studies · 183 participants | Low |
Intervention NR Shoulder range of motion for abduction ‐ medium term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment Conservative interventions for preventing clinically detectable upper‐limb lymphoedema in patients who are… (2015) · Cochrane | no estimate extracted | 3 studies · 183 participants | Very low |
Intervention NR Shoulder range of motion for forward flexion ‐ medium term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment Conservative interventions for preventing clinically detectable upper‐limb lymphoedema in patients who are… (2015) · Cochrane | no estimate extracted | 3 studies · 183 participants | Very low |
Early shoulder mobilising exercises vs delayed shoulder mobilising exercises Lymphoedema ‐ medium term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment Conservative interventions for preventing clinically detectable upper‐limb lymphoedema in patients who are… (2015) · Cochrane | RR 1.69 [0.94, 3.01] | 3 studies · 378 participants | Very low |
Early shoulder mobilising exercises vs delayed shoulder mobilising exercises Shoulder range of motion for abduction ‐ short term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment Conservative interventions for preventing clinically detectable upper‐limb lymphoedema in patients who are… (2015) · Cochrane | no estimate extracted | 2 studies · 262 participants | Very low |
Surgery vs primary endocrine therapy Survival ‐ overall · Women (70 years plus )with operable primary breast cancer Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus) (2014) · Cochrane | HR 0.98 [0.81, 1.2] | 3 studies · 495 participants | Low |
Surgery plus endocrine therapy vs primary endocrine therapy Survival ‐ overall · Women (70 years plus) with operable primary breast cancer Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus) (2014) · Cochrane | HR 0.86 [0.73, 1] | 3 studies · 1076 participants | Low |
Surgery plus endocrine therapy vs primary endocrine therapy Local disease control · Women (70 years plus) with operable primary breast cancer Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus) (2014) · Cochrane | HR 0.28 [0.23, 0.35] | 2 studies · 929 participants | High |
Intervention NR Overall survival · patients with HER2‐positive metastatic breast cancer Trastuzumab‐containing regimens for metastatic breast cancer (2014) · Cochrane | HR 0.82 [0.71, 0.94] | 5 studies · 1309 participants | Moderate |
Intervention NR Progression‐free survival · patients with HER2‐positive metastatic breast cancer Trastuzumab‐containing regimens for metastatic breast cancer (2014) · Cochrane | HR 0.61 [0.54, 0.7] | 7 studies · 1489 participants | Moderate |
Intervention NR Congestive heart failure · patients with HER2‐positive metastatic breast cancer Trastuzumab‐containing regimens for metastatic breast cancer (2014) · Cochrane | RR 3.49 [1.88, 6.47] | 7 studies · 1459 participants | Moderate |
Fibrin glue instillation under skin flaps vs no‐fibrin Incidence of postoperativeseromaRR · people with breast and axillary surgery Fibrin glue instillation under skin flaps to prevent seroma‐related morbidity following breast and axillary… (2013) · Cochrane | RR 1.02 [0.9, 1.16] | 18 studies · 1252 participants | Low |
Fibrin glue instillation under skin flaps vs no‐fibrin Mean volume of seromaSMD · people with breast and axillary surgery Fibrin glue instillation under skin flaps to prevent seroma‐related morbidity following breast and axillary… (2013) · Cochrane | no estimate extracted | 10 studies · 731 participants | Low |
Fibrin glue instillation under skin flaps vs no‐fibrin Total volume of drained seromaSMD · people with breast and axillary surgery Fibrin glue instillation under skin flaps to prevent seroma‐related morbidity following breast and axillary… (2013) · Cochrane | no estimate extracted | 13 studies · 888 participants | Low |
Fibrin glue instillation under skin flaps vs no‐fibrin Number of days for persistent drainageSMD · people with breast and axillary surgery Fibrin glue instillation under skin flaps to prevent seroma‐related morbidity following breast and axillary… (2013) · Cochrane | no estimate extracted | 13 studies · 861 participants | Low |
Fibrin glue instillation under skin flaps vs no‐fibrin Surgical site infectionRR · people with breast and axillary surgery Fibrin glue instillation under skin flaps to prevent seroma‐related morbidity following breast and axillary… (2013) · Cochrane | RR 1.05 [0.63, 1.77] | 13 studies · 1009 participants | Low |
Fibrin glue instillation under skin flaps vs no‐fibrin PostoperativecomplicationsRR · people with breast and axillary surgery Fibrin glue instillation under skin flaps to prevent seroma‐related morbidity following breast and axillary… (2013) · Cochrane | RR 1.13 [0.63, 2.04] | 11 studies · 981 participants | Low |
Fibrin glue instillation under skin flaps vs no‐fibrin Length of hospital staySMD · people with breast and axillary surgery Fibrin glue instillation under skin flaps to prevent seroma‐related morbidity following breast and axillary… (2013) · Cochrane | no estimate extracted | 6 studies · 364 participants | Low |
Intervention NR Overall survival (OS) · HER2‐positive early breast cancer patients Trastuzumab containing regimens for early breast cancer (2012) · Cochrane | HR 0.66 [0.57, 0.77] | 8 studies · 9945 participants | High |
Intervention NR Disease free survival (DFS) · HER2‐positive early breast cancer patients Trastuzumab containing regimens for early breast cancer (2012) · Cochrane | HR 0.6 [0.5, 0.71] | 8 studies · 9935 participants | High |
Intervention NR Congestive heart failure (CHF) · HER2‐positive early breast cancer patients Trastuzumab containing regimens for early breast cancer (2012) · Cochrane | RR 5.11 [3, 8.72] | 8 studies · 10281 participants | High |
Intervention NR Left ventricular ejection fraction decline (LVEF) · HER2‐positive early breast cancer patients Trastuzumab containing regimens for early breast cancer (2012) · Cochrane | RR 1.83 [1.36, 2.47] | 7 studies · 7939 participants | Moderate |
Intervention NR Brain metastasis as first site of relapse · HER2‐positive early breast cancer patients Trastuzumab containing regimens for early breast cancer (2012) · Cochrane | RR 1.75 [1.29, 2.38] | 5 studies · 6881 participants | Low |
Intervention NR Febrile neutropenia Rates of patients · breast cancer patients undergoing chemotherapy Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile… (2012) · Cochrane | RR 0.27 [0.11, 0.7] | 6 studies · 2073 participants | Moderate |
Intervention NR Injection‐site reaction Rates of patients · breast cancer patients undergoing chemotherapy Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile… (2012) · Cochrane | RR 3.59 [2.33, 5.53] | 2 studies · 262 participants | Moderate |
Intervention NR Early mortality Rates of patients · breast cancer patients undergoing chemotherapy Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile… (2012) · Cochrane | RR 0.32 [0.13, 0.77] | 8 studies · 2143 participants | Low |
Intervention NR Infection‐related mortality Rates of patients · breast cancer patients undergoing chemotherapy Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile… (2012) · Cochrane | RR 0.14 [0.02, 1.29] | 8 studies · 2143 participants | Low |
Intervention NR Severe neutropenia (WHO grade IV) Rates of patients · breast cancer patients undergoing chemotherapy Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile… (2012) · Cochrane | RR 0.44 [0.17, 1.18] | 4 studies · 712 participants | Moderate |
Intervention NR Infections Rates of patients · breast cancer patients undergoing chemotherapy Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile… (2012) · Cochrane | RR 0.86 [0.72, 1.02] | 3 studies · 210 participants | Low |
Intervention NR Hospitalization Rates of patients · breast cancer patients undergoing chemotherapy Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile… (2012) · Cochrane | RR 0.14 [0.06, 0.3] | 4 studies · 1149 participants | Low |
Intervention NR Antibiotics (i.v.) Rates of patients · breast cancer patients undergoing chemotherapy Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile… (2012) · Cochrane | RR 0.35 [0.22, 0.55] | 4 studies · 1568 participants | Low |
Intervention NR Chemotherapy Rates of patients who received the planned chemotherapy doses at scheduled times and doses · breast cancer patients undergoing chemotherapy Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile… (2012) · Cochrane | RR 1.05 [0.97, 1.13] | 4 studies · 1588 participants | Low |
Intervention NR Bone pain Rates of patients · breast cancer patients undergoing chemotherapy Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile… (2012) · Cochrane | RR 5.88 [2.54, 13.6] | 3 studies · 388 participants | Moderate |
SoF vitamin E vs placebo Frequency of hot flushes Number of hot flushes per day ( · patients with hot flushes in women with a history of breast cancer Non‐hormonal interventions for hot flushes in women with a history of breast cancer (2010) · Cochrane | no estimate extracted | 1 study · 104 participants | High |
SoF vitamin E vs placebo Hot flushes score Number of HF x severity (from 1 to 4) ( · patients with hot flushes in women with a history of breast cancer Non‐hormonal interventions for hot flushes in women with a history of breast cancer (2010) · Cochrane | no estimate extracted | 1 study · 104 participants | High |
SoF gabapentin vs placebo Frequency of hot flushes Number of hot flushes per day ( · patients with hot flushes in women with a history of breast cancer Non‐hormonal interventions for hot flushes in women with a history of breast cancer (2010) · Cochrane | no estimate extracted | 1 study · 233 participants | High |
SoF gabapentin vs placebo Hot flushes score Number of HF x severity (from 1 to 4) ( · patients with hot flushes in women with a history of breast cancer Non‐hormonal interventions for hot flushes in women with a history of breast cancer (2010) · Cochrane | no estimate extracted | 1 study · 233 participants | High |